Telerehabilitation and pharmacological pain management approaches were tested in patients with advanced cancers, including prostate cancer, to see if pain and function could be improved.
Researchers compared the newly developed PRIMA-PI risk score against FLIPI and FLIPI-2 in patients with follicular lymphoma.
Researchers tested the combination of isatuximab with dexamethasone and pomalidomide in patients with relapsed or refractory multiple myeloma.
Cancer Network spoke with Lecia V. Sequist, MD, MPH, about the TATTON study, which tested the combination of osimertinib and savolitinib in previously treated non–small-cell lung cancer patients.
Researchers tested the addition of adjuvant chemotherapy to androgen suppression and radiotherapy in patients with localized high-risk prostate cancer.
A retrospective study supported the role of primary radiotherapy in early-stage follicular lymphoma.
Researchers have identified a potential new target for CAR T-cell therapy in patients with multiple myeloma.
A genomic and proteomic analysis of HER2+ breast cancer cell lines that are resistant to trastuzumab found a deregulation of the cell death pathway known as TRAIL.
Researchers tested the PI3K inhibitor umbralisib in patients with relapsed/refractory marginal zone lymphoma in a phase II study that was presented at the AACR Annual Meeting.
Researchers looked at the trends and risk factors for opioid-related hospitalizations among patients with cancer.